NCT03413800View on ClinicalTrials.gov

Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 12, 2018

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions
Relapsed Hematologic MalignancyMultiple Myeloma
Interventions
DRUG

Lenalidomide-Dexamethasone-DLI

Lenalidomide (Len) and Dexamethasone (Dex) for 6 months followed by three donor lymphocyte infusions (DLIs)

Trial Locations (1)

H1T2M4

CIUSSS de l'Est-de-l'île-de-Montréal, Installation Hôpital Maisonneuve Rosemond, Montreal

Sponsors

Collaborators (2)

Celgene
C3i Center Inc.
All Listed Sponsors
collaborator

Celgene

INDUSTRY

collaborator

C3i Center Inc.

UNKNOWN

lead

Ciusss de L'Est de l'Île de Montréal

OTHER